[ExacTech--a new measuring system for personal control of blood glucose]. / ExacTech--ein neues Messsystem zur Blutzuckerselbstkontrolle.

ExacTech is a pen-sized glucose meter that uses an amperometric principle for blood glucose determination. Accuracy was assessed in 94 capillary blood samples by comparing the ExacTech values to the hexokinase method. Correlation between the methods was 0.983. 76% of ExacTech measurements were within +/- 10% of the reference method. Coefficients of variation for within run precision determined in two different blood glucose levels were 3.2% (81 mg/dl) and 4.2% (222 mg/dl) resp. 12 diabetic patients compared ExacTech to their reflectance meters. The ExacTech readings when correlated with the hexokinase method gave slightly better results than those obtained with common glucose meters. Patients acceptability of this novel measuring system was excellent.

[Comparison of the accuracy and precision of 7 reflectometers in self-control of blood glucose]. / Vergleich von Richtigkeit und Präzision bei 7 Reflektometern zur Blutzuckerselbstkontrolle.

7 types of reflectance meters (Hypocount GA and MXB, Glucometer II and M, Petita B and B II, Reflolux II) were tested for accuracy and for within-run precision. To test the accuracy blood sugar was measured in 30 venous blood samples in the blood glucose ranges from 30 to 70, 71 to 180 and 181 to 300 mg/dl resp. on 4 instruments of each meter-type and by the hexokinase method as a reference method. With Hypocount MXB and Glucometer II great differences between correlation coefficients within the 4 instruments occurred. In the low blood glucose range all meters correlated best with the hexokinase method whereas poorer results were obtained in the low and the high glucose range. As regards the mean percental deviation, Reflolux II correlated closely with the reference method in the blood glucose range from 30 to 70 mg/dl, Hypocount MXB in the range from 71 to 180 mg/dl and Petita B in the range from 181-300 mg/dl. The greatest differences were found with both types of Hypocount- and Petita-meters in low blood sugar levels. With none of the tested meters a linear correlation with the hexokinase method was observed over the whole blood glucose range. Coefficients of variation for within-run precision ranged from 1.9% (Reflolux II) to 8.1% (Hypocount GA) depending on blood glucose concentration.

[Comparison of glibenclamide, gliquidone, glisoxepide and placebo in maturity onset diabetics of differing degrees of severity (author's transl)]. / Vergleich von Glibenclamid, Gliquidon, Glisoxepid und Plazebo an Erwachsenendiabetikern mit unterschiedlichem Schweregrad des Diabetes.

The purpose of the study was to investigate whether the potency of effect on the beta cell differs with type of sulfonylurea (SU) and with degree of severity of diabetes. 12 maturity onset diabetics were classed according to fasting blood glucose (FBG) in three groups of 4 patients each. Each patient served as his own control. Glibenclamide, Gliquidone, Glusoxepide and placebo were administered in random order with degree dosage adjusted according to degree of severity of diabetes. All patients were given a standardized diet with 150 g carbohydrates per day. Fullday profiles of blood glucose, insulin, C-peptide and sulfonylurea level in serum were made on the third day under each preparation. Results showed that with proper nutrition and sufficient weight reduction, patients in group I (FBG 80--130 mg/dl) needed no oral medication and in fact showed a tendency towards hypoglycaemic episodes under oral therapy. In group II (FBG 130--200 mg/dl) the effect of nutrients on beta cell secretion appeared to be both enhanced and accelerated by SU administration. Satisfactory metabolic control was achieved with SU, but not with placebo. This group seems to represent the type of patient most likely to benefit from SU therapy. In spite of high dosage levels, satisfactory control was not achieved with SU in any patient in group III (FBG greater than 200 mg/dl). Depending on individual factors such as ketosis-proneness, vascular complications, age and psycho-social aspects, insulin administration should be considered for these patients. There were not differences between the individual SU preparations in the parameters studied. There was insufficient evidence for a pharmacokinetic differential diagnosis.